article thumbnail

January 31, 2024: Improving the Public’s Understanding of the FDA, in This Week’s PCT Grand Rounds

Rethinking Clinical Trials

In this Friday's PCT Grand Rounds, Susan Winckler of the Reagan-Udall Foundation for the FDA will present "Strategies for Improving Public Understanding of FDA and the Products It Regulates: Why Should We Care, and What Might We Do?" The Grand Rounds session will be held on Friday, February 2, 2024, at 1:00 pm eastern.

Cosmetics 152
article thumbnail

TN DCA issues circular asking pharmacists in medical shops to wear white coat and badges

AuroBlog - Aurous Healthcare Clinical Trials blog

Although provisions of the Pharmacy Practice Regulations (PPR) 2015 are not there in the Drugs and Cosmetics (D&C) Act 1940 but are framed under the Pharmacy Act 1948, the steps now being taken by the drugs control administration (DCA) in Tamil Nadu in a motive to strengthen the dispensing activities in pharmacies are completely agreeing […] (..)

Cosmetics 151
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

D&C Rules need revamp as there is no clause of compensation for ADRs: regulatory experts

AuroBlog - Aurous Healthcare Clinical Trials blog

Taking into account the four main components of regulator, industry, trade and patient/consumer in a medicine value supply chain, the Drugs and Cosmetics (D&C) Rules, 1945 and D&C Act, 1940 needs an urgent revamp as there is no clause of compensation for ADRs in patients, according to drug regulatory experts.

Cosmetics 149
article thumbnail

DCGI issues show cause notice to e-pharmacies for stocking & selling drugs in contravention to D&C Act

AuroBlog - Aurous Healthcare Clinical Trials blog

The Drug Controller General of India (DCGI) has issued a show cause notice to online pharmacies including Tata 1mg for allegedly stocking and selling drugs in contravention of the provisions of the Drugs and Cosmetics Act, 1940 and Rules, once again bringing back the long pending issue of lack of regulations on e-pharmacies under the […]

Pharmacy 134
article thumbnail

25 Reasons Why Pharmaceutical Companies Need a Unified Clinical Trial Management Platform

Cloudbyz

Clinical trials are the backbone of drug development, and managing these trials efficiently is paramount. In recent years, the need for a unified clinical trial management platform has become increasingly evident. Cost Efficiency: Centralized data management reduces administrative overhead, minimizing trial costs.

article thumbnail

Accelerating Consumer Product Research with Unified Clinical Trial Management Solutions

Cloudbyz

The pursuit for the most effective and safe products requires rigorous clinical research, which involves meticulous trial design, recruitment, data collection, and subsequent analysis. Consumer product clinical trials typically involve the evaluation of new formulations or ingredients for safety, efficacy, and user acceptability.

article thumbnail

FDA $7bn plans for 2024: disclose contract manufacturers, restart Cancer Moonshot

Pharmaceutical Technology

The FDA’s proposed FY2024 Budget tops $7bn, to be shared between drug, food, and cosmetics tasks and overheads such as buildings; this is $372m higher than in FY 2023, a 10% increase. Restarting Cancer Moonshot: +$48m, for a total of $50m for President Biden’s pet project. Source: FDA © GlobalData